(IN BRIEF) Sanofi has agreed to acquire UK-based Vicebio for $1.15 billion upfront plus up to $450 million in milestones, with closing anticipated in Q4 2025. The deal adds an early-stage bivalent RSV/hMPV vaccine (VXB‑241, in Phase 1 for older adults) and … Read the full press release
Posted in Artificial Intelligence (AI), Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged acquisition, AI-powered biopharma, Daniel Watterson, Emmanuel Hanon, fully liquid combination vaccines, Jean-François Toussaint, Keith Chappell, lower respiratory tract infections, Medicxi, Molecular Clamp technology, non-mRNA vaccine, Older Adults, partnership, Paul Young, pneumonia, prefilled syringes, regulatory approvals, respiratory vaccines pipeline, seasonal surges, Tags: Sanofi, UniQuest, University of Queensland, Vicebio
(IN BRIEF) Final overall survival results from AstraZeneca’s FLAURA2 Phase III trial confirm that combining Tagrisso with chemotherapy significantly improves survival for patients with first-line advanced EGFR-mutated NSCLC. The data reinforce Tagrisso as the foundational therapy in this setting, building … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged ADAURA trial, ADAURA2, adjuvant therapy, AstraZeneca, cancer survival, chemotherapy, EGFRm NSCLC, EMA, FDA, FLAURA2 trial, global clinical trial, LAURA trial, lung cancer treatment, NeoADAURA, non-small cell lung cancer, oncology, osimertinib, overall survival, Pasi A. Jänne, pemetrexed, platinum-based treatment, progression-free survival, Susan Galbraith, Tagrisso, targeted therapy
(IN BRIEF) Sanofi has completed its purchase of Blueprint Medicines, acquiring the approved systemic mastocytosis therapy Ayvakit/Ayvakyt (avapritinib), along with two pipeline candidates: elenestinib (a KIT D816V inhibitor in Phase 2/3 HARBOR, NCT04910685) and BLU‑808 (a wild‑type KIT inhibitor). The $129.00‑per‑share … Read the full press release
Posted in Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged $129.00 per share, avapritinib, Ayvakit, Ayvakyt, Blueprint Medicines, BLU‑808, contingent rights, elenestinib, GIST, HARBOR, KIT inhibitor, MERGER, NASDAQ delisting, NCT04910685, partnership, PDGFRA D842V, Sanofi, SM, sustainability, systemic mastocytosis, tender offer
(IN BRIEF) The EIB has extended a €20 million venture debt facility to Solynta, a Dutch biotech firm specializing in true potato seeds, under the InvestEU initiative. This funding will accelerate Solynta’s hybrid breeding research, which replaces bulky, perishable tubers with … Read the full press release
Posted in Agriculture, Banks, Business, Environment, Financial, Food & Beverage, Government, Healthcare, Industrial, Investment, Luxembourg, Management, Marketing, Netherlands, News, Pharma & Biotech, Technology
Tagged climate resilience, disease resistance, EIB, European Investment Bank, food security, Gelsomina Vigliotti, hybrid breeding, InvestEU, Klasja van de Ridder, late blight, non‑GMO, partnership, Peter Poortinga, Solynta, sustainability, true potato seeds, United Nations Sustainable Development Goals, venture debt
(IN BRIEF) Novartis has appointed Mukul Mehta as CFO and Executive Committee member effective March 16, 2026. He will replace long‑time CFO Harry Kirsch, who retires on March 15, 2026, after 22 years at the company. Kirsch oversaw major strategic … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged 22-year career, Alcon spinoff, appointment, business planning and analysis, CFO appointment, digital finance, ECN, Executive Committee, focused medicines strategy, global finance leadership, GSK divestiture, Harry Kirsch, INSEAD, Jamnalal Bajaj Institute of Management Studies, leadership, March 16 2026, Mukul Mehta, Novartis, retirement, Roche divestiture, Sandoz spinoff, TAX, Vas Narasimhan
(IN BRIEF) Boehringer Ingelheim and LEO Pharma have agreed on a global license and transfer deal for SPEVIGO® (spesolimab), an antibody that blocks the IL‑36 receptor to treat generalized pustular psoriasis (GPP). LEO Pharma will assume worldwide commercialization and clinical development, harnessing … Read the full press release
Posted in Business, Denmark, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Technology
Tagged Boehringer Ingelheim, Christophe Bourdon, clinical development, commercialization, Dermatology, EUR 90 million, generalized pustular psoriasis, global license, GPP, IL‑36 receptor, LEO Pharma, monoclonal antibody, partnership, rare skin disease, Shashank Deshpande, spesolimab, SPEVIGO
(IN BRIEF) Bayer and M2i Group have extended their distribution partnership to cover Asia-Pacific, Latin America, and the United States, following a successful 2023 agreement in Europe and Africa. This exclusive deal will enable Bayer to market M2i’s pheromone gel … Read the full press release
Posted in Agriculture, Business, Environment, Financial, France, Germany, Government, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Technology
Tagged Asia-Pacific, Bayer, biological crop protection, complex molecules, digital crop-management, exclusive distribution, Latin America, M2i Group, partnership, pest monitoring, pheromone gels, Phillippe Guerret, Press technology, Ralf Glaubitz, sustainability, sustainable agriculture, United States, VYNYTY Press series
(IN BRIEF) Fresenius Kabi’s Santiago de Besteiros plant in Portugal has secured BSI Kitemark™ Certification for Minimized Risk of AMR in its Ceftriaxone production, confirming compliance with the AMR Industry Alliance’s Antibiotic Manufacturing Standard. Key measures include stringent controls to … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Portugal, Science, Technology
Tagged AMR, AMR Industry Alliance, antibiotic efficacy, Antibiotic Manufacturing Standard, antimicrobial resistance, BSI Kitemark Certification, Ceftriaxone, Cristina Fernandes, EHS Management, emissions control, environmental protection, Fresenius Kabi, partnership, PORTUGAL, responsible pharmaceutical production, Santiago de Besteiros, sustainability, wastewater management, Zyad Hatquai
(IN BRIEF) The EIB has extended a €150 million loan to Alfasigma to fund its R&D efforts from 2025 to 2027, targeting new drugs in gastroenterology, hepatology, vascular medicine, rheumatology, and rare diseases. The financing, endorsed by EIB Vice-President Gelsomina … Read the full press release
Posted in Banks, Business, Economy, Financial, Government, Healthcare, Industrial, Investment, Italy, Luxembourg, Management, Marketing, News, Pharma & Biotech, Science, Technology
Tagged Alfasigma, biopharmaceutical innovation, EIB, European competitiveness, European Investment Bank, gastroenterology, Gelsomina Vigliotti, hepatology, job creation, partnership, patient-centred therapies, R&D financing, rare diseases, rheumatology, specialty care, Tatiana Simonelli, Vascular Medicine
(IN BRIEF) Basilea Pharmaceutica has secured an extra USD 39 million from BARDA under its Other Transaction Agreement, bringing potential non-dilutive funding to USD 268 million over 12 years. This new tranche will finance the ongoing phase 3 trial of … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged Allschwil, antibacterial, antifungal, ASPR, BAL2062, BARDA, Basilea Pharmaceutica Ltd, Cresemba®, fosmanogepix, HHS, invasive candidiasis, invasive mold infections, multidrug-resistant Candida auris, orphan drug, Other Transaction Agreement, partnership, QIDP, Switzerland, Zevtera®
(IN BRIEF) Boehringer Ingelheim has initiated the THULITE Phase II trial (NCT06962839) to assess BI 1815368, a novel oral agent for diabetic macular edema (DME). Affecting more than 21 million people globally, DME is typically managed by frequent eye injections, … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Technology
Tagged at-home treatment, BI 1815368, BI 764524, biopharmaceutical research, Boehringer Ingelheim, Charles C. Wykoff, clinical trial NCT06962839, CRIMSON trial, Dario Madani, diabetic macular edema, diabetic retinal disease, DME, intravitreal injections, macular edema, oral therapy, Patrick Bussfeld, PRO RETINA, retinal vascular hyperpermeability, Sema3A antibody, THULITE Phase II, vision loss
A European collaboration developing predictive tools to personalise aortic surgery, enhance prosthesis selection, and support clinical decision-making (IN BRIEF) PANDORA is an EU-funded collaboration uniting LivGemini, RBF Morph, INSA and UnivREN—alongside Rennes University Hospital—to create patient-specific “digital twins” of the … Read the full press release
Posted in Artificial Intelligence (AI), European Union, France, Healthcare, Italy, Pharma & Biotech, Science, Technology
Tagged 3D models, AIinCardiology, Ansys, Aortic Aneurysms, aortic surgery, AorticAneurysm, AorticSurgery, artificial intelligence, B2B2B approach, biomedical engineer, cardiovascular numerical simulation, Cardiovascular Surgery, CardiovascularHealth, CardiovascularSimulation, Dacron prostheses, datasets, DigitalHealth, DigitalTwin, epidemiological studies, EU-funded, FFplus consortium, H2020 project, HorizonEurope, HPCinHealthcare, In-Silico Modelling, INSA, InSilicoMedicine, InSilicoSurgery, Institut National des Sciences Appliquées, Leonardo Geronzi PhD, LivGemini, LTSI laboratory, Medical Device Manufacturers, medical image analysis, MedicalImageAnalysis, MeDiTATe, MedTechInnovation, mesh morphing algorithms, NumericalSimulation, PANDORA, Pandora Project, PANDORAproject, para-anastomotic aneurysms, post-implant prosthesis kinking, post-surgery coronary perfusion, predictive assessment of aortic surgery outcomes, predictive tools, PredictiveSurgery, prosthesis, RBF Morph, SurgicalPlanning, Université de Rennes, University Hospital of Rennes, UnivREN
(IN BRIEF) The European Commission has approved AstraZeneca’s Imfinzi (durvalumab) combined with gemcitabine and cisplatin as neoadjuvant therapy, followed by Imfinzi adjuvant monotherapy, for adults with resectable muscle-invasive bladder cancer. This approval is anchored in NIAGARA Phase III trial data … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged adjuvant monotherapy, AstraZeneca, cisplatin, curative intent, Dave Fredrickson, durvalumab, ESMO, European Commission, event-free survival, gemcitabine, Imfinzi, immunotherapy, MIBC, Michiel Van der Heijden, muscle-invasive bladder cancer, neoadjuvant chemotherapy, New England Journal of Medicine, NIAGARA Phase III, NMIBC, overall survival, radical cystectomy
(IN BRIEF) Roche has revealed that Dr. Hans Clevers, Head of Pharma Research and Early Development and board member since 2019, will retire from his pRED role at the end of August, though he will continue leading the Institute of … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged appointment, Barbara Schädler, Board of Directors, corporate executive committee, COVID-19, Group Communications, Hans Clevers, Institute of Human Biology, Johannes Clevers, ledership, Pharma Research and Early Development, pRED, retirement, Roche, succession planning, Thomas Schinecker
(IN BRIEF) The FDA has awarded orphan drug designation to Sanofi’s riliprubart for the treatment of antibody-mediated rejection in solid organ transplants, highlighting the therapy’s potential in an area lacking approved options. Riliprubart, a humanized IgG4 antibody targeting activated C1s … Read the full press release
Posted in Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Security & Safety, Technology
Tagged Alyssa Johnsen, AMR, antibody-mediated rejection, C1s inhibition, chronic inflammatory demyelinating polyneuropathy, CIDP, ClinicalTrials.gov, complement pathway, FDA, Global Therapeutic Area Development Head, immunology, MOBILIZE, NCT05156710, NCT06290128, NCT06290141, orphan drug designation, Phase 2 study, riliprubart, Sanofi, SAR445088, solid organ transplantation, VITALIZE
(IN BRIEF) Roche presented positive phase I/II data for NXT007, its Chugai-engineered bispecific antibody for haemophilia A, at the 2025 ISTH Congress. In the NXTAGE study’s highest-dose cohorts (B-3 and B-4), none of the 30 participants experienced bleeds requiring treatment, … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged bispecific antibody, Chugai, clinical development, emicizumab, global supply chain, Haemophilia A, haemostatic normalisation, Hemlibra, ISTH Congress 2025, Levi Garraway, NXT007, NXTAGE study, phase I/II data, Roche, subcutaneous dosing, thromboembolic events
(IN BRIEF) GSK’s marketing authorisation application for linerixibat, an investigational ileal bile acid transporter inhibitor, has been accepted for review by the European Medicines Agency. The submission is supported by GLISTEN Phase III trial data showing that linerixibat rapidly and … Read the full press release
Posted in Business, Healthcare, Pharma & Biotech, United Kingdom
Tagged alcohol-related liver disease, bile acid transporter, cholestatic pruritus, chronic hepatitis B, EASL Congress, EMA, European Medicines Agency, FDA, GLISTEN trial, GSK, IBAT inhibitor, itch-related sleep interference, Kaivan Khavandi, linerixibat, Marketing Authorisation Application, MASH, NCT04950127, orphan drug designation, PBC, Phase III, primary biliary cholangitis, UK regulatory review
(IN BRIEF) The CHMP has recommended EU approval of Sarclisa alongside VRd for transplant-eligible NDMM, based on GMMG-HD7 trial results showing superior MRD negativity and PFS compared to VRd alone. This potential label extension would mark Sarclisa’s fourth EU approval … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged ASH 2024, autologous stem cell transplant, bortezomib, CHMP, dexamethasone, European Medicines Agency, GMMG-HD7, isatuximab, Journal of Clinical Oncology, lenalidomide, MRD negativity, Multiple Myeloma, NDMM, phase 3 study, progression-free survival, Sanofi, Sarclisa, transplant-eligible, VRd
(IN BRIEF) Merck has awarded its 2025 North American Advance Biotech Grant to Neoclease, a Boston-based startup developing AI-designed gene-editing therapies for Parkinson’s disease and other monogenic disorders. Neoclease will benefit from Merck’s technologies, contract testing, regulatory guidance, and hands-on … Read the full press release
Posted in Artificial Intelligence (AI), Awards, Business, Financial, Germany, Healthcare, Management, Pharma & Biotech, Science, Technology
Tagged 2025 North American winner, Advance Biotech Grant, AI in biotech, Boston biotech, early-stage biotech support, Emprove program, gene-editing therapies, life sciences innovation, M Lab Collaboration Center, Merck, monogenic diseases, NCX-L2, Neoclease, Parkinson's disease, Sebastian Arana, synthetic biology
(IN BRIEF) The University of Copenhagen, in collaboration with Rigshospitalet, has introduced a clinically validated gene-editing method to identify harmful inherited mutations that raise cancer risk. Developed at the university’s Biotech Research and Innovation Center, the CRISPR-Select technique allows scientists … Read the full press release
Posted in Denmark, Education, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged BRCA2, breast cancer, BRIC, cancer diagnosis, cancer risk, CRISPR-Select, gene editing, genetic testing, genomic medicine, hereditary cancer, Maria Rossing, ovarian cancer, personalized medicine, Rigshospitalet, The Journal of Clinical Investigation, University of Copenhagen, variant classification
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?